JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pogrund, R. S.
Right arrow Articles by Clark, W. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pogrund, R. S.
Right arrow Articles by Clark, W. G.
Journal of Pharmacology And Experimental Therapeutics, Vol. 131, Issue 3, 294-307, 1961
Copyright © 1961 by American Society for Pharmacology and Experimental Therapeutics


METABOLISM OF 3-HYDROXY- AND 3,4-DIHYDROXYPHENYLPYRUVIC ACIDS IN VIVO

Robert S. Pogrund 1, William Drell 2, and William G. Clark 3

1 Aerospace Corporation, P.O. Box 95085, Los Angeles 45, California
2 California Corporation for Biochemical Research, Los Angeles 63, California
3 Department of Physiological Chemistry, University of California School of Medicine, Los Angeles, California

In confirmation of the work of others L-3,4-dihydroxyphenylalanine (dopa) increases the blood pressure when injected intravenously, due to its decarboxylation to dopamine by dopa decarboxylase in vivo. This pressor response is prevented by prior injection of a dopa decarboxylase inhibitor, 5-(3-hydroxycinnamoyl) salicylic acid (HCS). The dopamine formed and excreted in the urine has been isolated and identified, and the amount formed is decreased by HCS.

m-Tyrosine also increases the blood pressure, due to the decarboxylated product m-tyramine, which was isolated from the urine. This decarboxylation also is blocked by HCS, as reflected by a decreased pressor response and excretion of m-tyramine. The chief metabolic products of m-tyrosine in the cat are m-hydroxyphenylacetic acid and m-hydroxyphenylaceturic acid.

m-Hydroxyphenylpyruvic and 3,4-dihydroxyphenylpyruvic acids increase the blood pressure of cats and rats when administered intravenously. It is shown that this is due to transaminiation to time corresponding amino acids, m-tyrosine and dopa, respectively, and their subsequent decarboxylation to m-tyramine and dopamine respectively. The m-tyrosine and m-tyramine have been isolated from the urine and identified.

HCS decreases the amount of m-tyramine formed from m-hydroxyphenylpyruvic acid.

m-Hydroxyphenylpyruvic acid administration in cats also leads to the urinary excretion of m-hydroxyphenylacetic acid and m-hydroxyphenyllactic acid.

Pyridoxine deficiency decreases kidney and liver dopa decarboxylase apoenzyme and coenzyme, with a greater effect on liver apoenzyme. This is reflected in a decreased blood pressure response to dopa and 3,4-dihydroxyphenylpyruvic acid.

p-Hydroxyphenylpyruvic acid, DL-phenylalanine and L-tyrosine have no pressor effects, and no urinary tyramine or phenylethylamine can be detected after the administration of the latter two compounds to cats and rats pretreated with iproniazid.

Submitted on July 27, 1960







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1961 by the American Society for Pharmacology and Experimental Therapeutics.